Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsules | The Financial Express

Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsules

The approval granted by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Mesalamine Extended-Release Capsules of strength 0.375 g, the company said in a statement.

Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsules
AstraZeneca also said that its drug Imfinzi failed the main goal of a late-stage study in patients with a form of late-stage lung cancer. (File)

Alembic Pharmaceuticals on Wednesday said it has received final approval from the US health regulator for its generic Mesalamine extended-release capsules indicated for the maintenance of remission of ulcerative colitis in adults.

The approval granted by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Mesalamine Extended-Release Capsules of strength 0.375 g, the company said in a statement.

Also read| USFDA approves Alembic Pharmaceuticals’ Chlorthalidone Tablets USP, 25 mg and 50 mg

The approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc’s reference listed drug (RLD), Apriso extended-release capsules, 0.375 g, it added.

Also read| Roche’s drug improves sight of people with vision-threatening eye disorder

The drug has an estimated market size of USD 133 million for the months ended June 2022, Alembic said citing IQVIA data.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 02-11-2022 at 11:20 IST